Stockscreener 앱 받기
16.64
0.24%
0.04
시간 외 거래:
16.64
전일 마감가:
$16.60
열려 있는:
$16.64
하루 거래량:
614.13K
Relative Volume:
0.74
시가총액:
$767.55M
수익:
$681.75M
순이익/손실:
$70.47M
주가수익비율:
184.89
EPS:
0.09
순현금흐름:
$173.19M
1주 성능:
-4.91%
1개월 성능:
-4.86%
6개월 성능:
-46.01%
1년 성능:
-40.34%
1일 변동 폭
$16.00
$16.82
1주일 범위
$16.00
$17.54
52주 변동 폭
$11.16
$35.95
Pacira Biosciences Inc Stock (PCRX) Company Profile
명칭
Pacira Biosciences Inc
전화
813-553-6680
주소
5401 WEST KENNEDY BOULEVARD, TAMPA, NJ
PCRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| PCRX | 16.64 | 767.55M | 681.75M | 70.47M | 173.19M | 0.09 |
| ZTS | 176.42 | 79.51B | 9.15B | 2.43B | 2.31B | 4.92 |
| TAK | 13.53 | 42.89B | 30.27B | 1.93B | 3.45B | 0.444 |
| HLN | 9.43 | 42.57B | 14.26B | 1.55B | 0 | 0.3327 |
| TEVA | 16.49 | 18.51B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.00 | 15.37B | 15.24B | -646.50M | 1.88B | 1.53 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-20 | 개시 | Raymond James | Outperform |
| 2023-08-03 | 업그레이드 | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | 재개 | Wedbush | Outperform |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-01-03 | 재개 | JP Morgan | Overweight |
| 2021-07-26 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-04-21 | 재개 | JP Morgan | Neutral |
| 2021-04-09 | 개시 | Berenberg | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-02-11 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | 재확인 | Needham | Buy |
| 2020-05-27 | 개시 | Guggenheim | Neutral |
| 2020-04-07 | 개시 | Northland Capital | Outperform |
| 2020-03-20 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-24 | 개시 | SunTrust | Buy |
| 2020-01-23 | 개시 | SunTrust | Buy |
| 2019-11-06 | 개시 | BTIG Research | Buy |
| 2019-06-11 | 개시 | Barclays | Overweight |
| 2019-05-06 | 업그레이드 | Mizuho | Underperform → Neutral |
| 2019-05-02 | 업그레이드 | Stifel | Sell → Hold |
| 2019-02-01 | 다운그레이드 | Mizuho | Neutral → Underperform |
| 2018-08-06 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-21 | 재확인 | Mizuho | Neutral |
| 2018-02-16 | 다운그레이드 | Needham | Buy → Hold |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2018-01-04 | 재확인 | Canaccord Genuity | Buy |
| 2018-01-03 | 개시 | Leerink Partners | Mkt Perform |
모두보기
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
52,708 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Purchased by Janney Montgomery Scott LLC - MarketBeat
Impax Asset Management Group plc Boosts Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
PCRXPacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan
Pacira Announces 104-Week Safety and Efficacy Data - GlobeNewswire
When (PCRX) Moves Investors should Listen - Stock Traders Daily
Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock Holdings Lifted by Los Angeles Capital Management LLC - MarketBeat
Pacira BioSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Pacira BioSciences' SWOT analysis: stock faces patent challenges amid growth initiatives - Investing.com Canada
Pacira BioSciences Inc (PCRX) Stock Price Down 3.31% on Nov 12 - GuruFocus.com
Barclays Issues Pessimistic Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price - MarketBeat
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences - GlobeNewswire
Pacira BioSciences to Present at Jefferies and Piper Sandler Healthcare Conferences | PCRX Stock News - StockTitan
Robeco Institutional Asset Management B.V. Invests $1.05 Million in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences Inc (PCRX) Worth Considering For The Next Few Weeks - Stocks Register
Pacira BioSciences' (PCRX) Buy Rating Reaffirmed at Needham & Company LLC - MarketBeat
Brokerages Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $24.20 - Defense World
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2024 Earnings Call Transcript - Insider Monkey
This Pacira BioSciences Insider Reduced Their Stake By 85% - Simply Wall St
Evaluating Pacira BioSciences: Insights From 8 Financial Analysts - Benzinga
Royal Bank of Canada Forecasts Strong Price Appreciation for Pacira BioSciences (NASDAQ:PCRX) Stock - MarketBeat
Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth - Yahoo Finance
Pacira Pharmaceuticals stock target increased post Q3 earnings report By Investing.com - Investing.com UK
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance
Pacira BioSciences Reports Q3 2024 Earnings and Strategic Developments - TipRanks
Pacira BioSciences Inc (PCRX) Reports Q3 2024 Revenue of $168.6M, EPS Misses Estimates with $3.11 Loss - GuruFocus.com
Pacira BioSciences Reports Third Quarter 2024 Financial Results - The Manila Times
Pacira BioSciences Reports $168.6M Revenue, Hit by $163.2M Impairment Charge in Q3 | PCRX Stock News - StockTitan
Impax Asset Management Group plc Has $7.08 Million Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Insights into Pacira BioSciences's Upcoming Earnings - Benzinga
Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Kn - GuruFocus.com
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives $24.20 Consensus Target Price from Analysts - MarketBeat
Trading (PCRX) With Integrated Risk Controls - Stock Traders Daily
Rice Hall James & Associates LLC Sells 730,288 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira BioSciences (PCRX) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
Allspring Global Investments Holdings LLC Buys 93,497 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 - GlobeNewswire
Assenagon Asset Management S.A. Buys 419,656 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat
Shawn Cross appointed as chief financial officer for Pacira Biosciences - Pharmafile
When the Price of (PCRX) Talks, People Listen - Stock Traders Daily
Pacira BioSciences appoints Shawn Cross as CFO By Investing.com - Investing.com Australia
Pacira BioSciences appoints Shawn Cross as CFO - Investing.com
Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock? - MSN
Pacira BioSciences Appoints Shawn Cross As Chief Financial Officer - citybiz
Pacira BioSciences Names Shawn Cross Chief Financial Officer - MarketWatch
Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - The Manila Times
Q1 EPS Estimate for Pacira BioSciences Reduced by Analyst - MarketBeat
Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Wedge Capital Management L L P NC - MarketBeat
Pacira BioSciences Inc (PCRX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Pacira Biosciences Inc (PCRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
0.15%
자본화:
|
볼륨(24시간):